VIR-5500
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone-refractory Prostate Cancer
Conditions
Hormone-refractory Prostate Cancer
Trial Timeline
Aug 10, 2023 → Sep 29, 2027
NCT ID
NCT05997615About VIR-5500
VIR-5500 is a phase 1 stage product being developed by Vir Biotechnology for Hormone-refractory Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05997615. Target conditions include Hormone-refractory Prostate Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Hormone-refractory Prostate Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05997615 | Phase 1 | Recruiting |
Competing Products
8 competing products in Hormone-refractory Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enzalutamide | Astellas Pharma | Phase 2 | 35 |
| YM598 | Astellas Pharma | Phase 2 | 27 |
| Zoledronic acid + Estramustine + Docetaxel | Novartis | Phase 2 | 35 |
| amg 162 | Amgen | Phase 3 | 40 |
| Denosumab | Amgen | Phase 3 | 40 |
| IV Bisphosphonate q 4 weeks | Amgen | Phase 2 | 35 |
| Dasatinib | Bristol Myers Squibb | Phase 2 | 35 |
| ILX651 | Sanofi | Phase 2 | 35 |